SEC Form 4 · accession 0001209191-17-040673
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D. Humphries
Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 16, 2017 · 7:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $24.58 | Jun 15, 2017 | A | 8,000 | A | — | Jun 14, 2027 | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date.